Akebia Therapeutics, Inc. - Common Stock (NQ:AKBA)

0.8265 -0.0469 (-5.37%)

Delayed Quote Updated: 1:40 PM EDT, Oct 8, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Akebia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Why JD.com Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

March 09, 2023

Gainers

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

March 09, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

March 09, 2023

Via Benzinga

Akebia Therapeutics Earnings Preview ↗

March 08, 2023

Via Benzinga

Looking Into Akebia Therapeutics's Return On Capital Employed ↗

November 18, 2022

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

October 20, 2022

Thursday saw 177 companies set new 52-week lows.

Via Benzinga

Akebia Therapeutics Return On Capital Employed Insights ↗

August 16, 2022

Via Benzinga

Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗

February 24, 2023

Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 24, 2023

Via Benzinga

Why Beyond Meat Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket ↗

February 24, 2023

Gainers Cingulate Inc (NASDAQ: CING) rose 85.7% to $2.08 in pre-market trading after the company disclosed top-line results from Fed/Fast study of lead asset CTx-1301 for ADHD.

Via Benzinga

Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study ↗

August 05, 2022

Via Benzinga

Akebia Therapeutics: Q2 Earnings Insights ↗

August 04, 2022

Akebia Therapeutics (NASDAQ:AKBA) reported its Q2 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

February 23, 2023

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

February 20, 2023

Via Benzinga

Why TripAdvisor Shares Are Trading Higher By 10%; Here Are 20 Stocks Moving Premarket ↗

February 15, 2023

Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 69.1% to $0.7948 in pre-market trading after the company requested withdrawal of registration statement.

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

February 15, 2023

We're starting off another day of trading with a breakdown of the biggest pre-market stock movers for trader need to kno about Wednesday!

Via InvestorPlace

12 Health Care Stocks Moving In Friday's After-Market Session ↗

February 10, 2023

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

February 10, 2023

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

February 02, 2023

Via Benzinga

Planned Government Move To Expand Access To Drugs For End-Stage Renal Disease Patients Could Shine The Spotlight On Unicycive ↗

December 07, 2022

In the U.S., reimbursement of dialysis expenses by the Centers for Medicare & Medicaid Services (CMS) is done using a prospective payment system (PPS) which enables the payout of a predetermined amount...

Via Benzinga

Akebia Therapeutics Earnings Preview ↗

November 02, 2022

Akebia Therapeutics (NASDAQ:AKBA) is set to give its latest quarterly earnings report on Thursday, 2022-11-03. Here's what investors need to know before the announcement. Analysts estimate that Akebia...

Via Benzinga

Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells

October 12, 2022

You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick?

Via TheNewswire.com

Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells ↗

October 11, 2022

You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick?

Via Benzinga

Why Missfresh Shares Are Trading Lower; Here Are 30 Stocks Moving Premarket ↗

October 10, 2022

Gainers M-tron Industries, Inc. (NASDAQ: MPTI) rose 57.9% to $24.00 in pre-market trading after surging 10% on Friday. M-tron Industries completed its earlier announced separation from The LGL Group,...

Via Benzinga

Why Kiora Pharmaceuticals Is Trading Lower By Around 22%; Here Are 26 Stocks Moving Premarket ↗

September 27, 2022

Gainers 9 Meters Biopharma, Inc. (NASDAQ: NMTR) rose 31.4% to $0.2720 in pre-market trading after the company disclosed final results from Phase 2 VIBRANT study, End-of-Phase 2 meeting with the FDA for...

Via Benzinga

How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication

September 23, 2022

By David Willey, Benzinga

Via News Direct

How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication

September 23, 2022

Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000...

Via TheNewswire.com

How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication ↗

September 22, 2022

Via Benzinga

Biotech Daily: Thumbs Down For Acadia's Antipsychotic Drug, Akebia Fails COVID-19 Study, Kazia's Encouraging Data In Brain Metastases ↗

August 05, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Why Amazon Is Trading Higher By 12%: Here Are 23 Stocks Moving Premarket ↗

July 29, 2022

Gainers Getty Images Holdings, Inc. (NYSE: GETY) rose 104.5% to $21.47 in pre-market trading.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.